Mendelian
United Kingdom
- London, England
- 03/03/2023
- Unknown
- $1,628,000
At Mendelian, our mission is to make rare diseases our priority. We have an amazing team who have built software, which enables doctors to help patients earlier, by finding the undiagnosed.
Did you know that rare diseases are not actually rare? More rare diseases are life-threatening condition that are collectively common. In fact, 1 in 17 of us will be affected by a rare disease in our lifetime. This is comparable to common diseases such as diabetes and asthma.
Rare disease symptoms often develop gradually and in different organ systems. This means patients present to different doctors for seemingly independent reasons making these diseases difficult to diagnose.
On average, rare disease patients experience 3 misdiagnoses, visit 5 different doctors and wait over 4 years before receiving a diagnosis in the UK. In the past decade, undiagnosed rare diseases have cost the NHS in excess of £3.4 billion.
- Industry Software Development
- Website https://www.mendelian.co/
- LinkedIn https://www.linkedin.com/company/mendelian/
Related People
Peter FishFounder
United Kingdom -
Cambridge, England
Medical doctor, scientist & entrepreneur. Passionate about genomics, personalised medicine & innovation in the medical world.
Amphix Bio | $12,500,000 | (Dec 19, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Katalist | $1,500,000 | (Dec 19, 2025)
Syremis Therapeutics | $165,000,000 | (Dec 19, 2025)
Gravity Labs Co., Ltd. | $17,000,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
InfiniteWatch | $4,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)
Neural Concept | $100,000,000 | (Dec 19, 2025)
SkillCorner | $60,000,000 | (Dec 19, 2025)
Wearlinq | $14,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)